From randomized trial to practice: Single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer

G. D. Aletti, D. Nordquist, L. Hartmann, M. Gallenberg, H. J. Long, William Arthur Cliby

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Patients and methods: All patients with stage IIIC OC consecutively operated at our institution from January 2006 to December 2007 were prospectively collected and analyzed. Results: Eighty-nine patients with stage IIIC OC optimally debulked were evaluated for this study. An i.p. port was primarily placed in 53 of 89 (60%), and i.p. chemotherapy was recommended in 55 patients. Reasons for not recommending i.p. chemotherapy in patients optimally debulked included postoperative complications (n = 7: 8%), poor nutritional/functional status (n = 5: 6%), and extensive surgery including bowel resection (n = 9: 10%). Thirty-three patients (33/55: 60%) recommended to receive i.p. chemotherapy-initiated i.p. treatment. Fifty-two percent of those beginning i.p. therapy (17/33) received three or more cycles with 36% (12/33) successfully completing six cycles. Reasons for discontinuation included grade 3-4 nephrotoxicity in 3 of 21 (14%), febrile neutropenia/sepsis in 3 of 21 (14%), port infection or malfunction in 8 of 21 (38%). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered.

Original languageEnglish (US)
Pages (from-to)1772-1778
Number of pages7
JournalAnnals of Oncology
Volume21
Issue number9
DOIs
StatePublished - Feb 5 2010

Fingerprint

Ovarian Neoplasms
Drug Therapy
Poisons
Febrile Neutropenia
Nutritional Status
Sepsis
Therapeutics
Infection

Keywords

  • I.p. chemotherapy
  • Ovarian cancer
  • Quality of care
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

From randomized trial to practice : Single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. / Aletti, G. D.; Nordquist, D.; Hartmann, L.; Gallenberg, M.; Long, H. J.; Cliby, William Arthur.

In: Annals of Oncology, Vol. 21, No. 9, 05.02.2010, p. 1772-1778.

Research output: Contribution to journalArticle

Aletti, G. D. ; Nordquist, D. ; Hartmann, L. ; Gallenberg, M. ; Long, H. J. ; Cliby, William Arthur. / From randomized trial to practice : Single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. In: Annals of Oncology. 2010 ; Vol. 21, No. 9. pp. 1772-1778.
@article{355c6d6141384de1b84c8b878e5f692b,
title = "From randomized trial to practice: Single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer",
abstract = "Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Patients and methods: All patients with stage IIIC OC consecutively operated at our institution from January 2006 to December 2007 were prospectively collected and analyzed. Results: Eighty-nine patients with stage IIIC OC optimally debulked were evaluated for this study. An i.p. port was primarily placed in 53 of 89 (60{\%}), and i.p. chemotherapy was recommended in 55 patients. Reasons for not recommending i.p. chemotherapy in patients optimally debulked included postoperative complications (n = 7: 8{\%}), poor nutritional/functional status (n = 5: 6{\%}), and extensive surgery including bowel resection (n = 9: 10{\%}). Thirty-three patients (33/55: 60{\%}) recommended to receive i.p. chemotherapy-initiated i.p. treatment. Fifty-two percent of those beginning i.p. therapy (17/33) received three or more cycles with 36{\%} (12/33) successfully completing six cycles. Reasons for discontinuation included grade 3-4 nephrotoxicity in 3 of 21 (14{\%}), febrile neutropenia/sepsis in 3 of 21 (14{\%}), port infection or malfunction in 8 of 21 (38{\%}). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered.",
keywords = "I.p. chemotherapy, Ovarian cancer, Quality of care, Toxicity",
author = "Aletti, {G. D.} and D. Nordquist and L. Hartmann and M. Gallenberg and Long, {H. J.} and Cliby, {William Arthur}",
year = "2010",
month = "2",
day = "5",
doi = "10.1093/annonc/mdq025",
language = "English (US)",
volume = "21",
pages = "1772--1778",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - From randomized trial to practice

T2 - Single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer

AU - Aletti, G. D.

AU - Nordquist, D.

AU - Hartmann, L.

AU - Gallenberg, M.

AU - Long, H. J.

AU - Cliby, William Arthur

PY - 2010/2/5

Y1 - 2010/2/5

N2 - Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Patients and methods: All patients with stage IIIC OC consecutively operated at our institution from January 2006 to December 2007 were prospectively collected and analyzed. Results: Eighty-nine patients with stage IIIC OC optimally debulked were evaluated for this study. An i.p. port was primarily placed in 53 of 89 (60%), and i.p. chemotherapy was recommended in 55 patients. Reasons for not recommending i.p. chemotherapy in patients optimally debulked included postoperative complications (n = 7: 8%), poor nutritional/functional status (n = 5: 6%), and extensive surgery including bowel resection (n = 9: 10%). Thirty-three patients (33/55: 60%) recommended to receive i.p. chemotherapy-initiated i.p. treatment. Fifty-two percent of those beginning i.p. therapy (17/33) received three or more cycles with 36% (12/33) successfully completing six cycles. Reasons for discontinuation included grade 3-4 nephrotoxicity in 3 of 21 (14%), febrile neutropenia/sepsis in 3 of 21 (14%), port infection or malfunction in 8 of 21 (38%). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered.

AB - Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Patients and methods: All patients with stage IIIC OC consecutively operated at our institution from January 2006 to December 2007 were prospectively collected and analyzed. Results: Eighty-nine patients with stage IIIC OC optimally debulked were evaluated for this study. An i.p. port was primarily placed in 53 of 89 (60%), and i.p. chemotherapy was recommended in 55 patients. Reasons for not recommending i.p. chemotherapy in patients optimally debulked included postoperative complications (n = 7: 8%), poor nutritional/functional status (n = 5: 6%), and extensive surgery including bowel resection (n = 9: 10%). Thirty-three patients (33/55: 60%) recommended to receive i.p. chemotherapy-initiated i.p. treatment. Fifty-two percent of those beginning i.p. therapy (17/33) received three or more cycles with 36% (12/33) successfully completing six cycles. Reasons for discontinuation included grade 3-4 nephrotoxicity in 3 of 21 (14%), febrile neutropenia/sepsis in 3 of 21 (14%), port infection or malfunction in 8 of 21 (38%). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered.

KW - I.p. chemotherapy

KW - Ovarian cancer

KW - Quality of care

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=77956098870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956098870&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq025

DO - 10.1093/annonc/mdq025

M3 - Article

C2 - 20139154

AN - SCOPUS:77956098870

VL - 21

SP - 1772

EP - 1778

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -